Showing 7211-7220 of 7612 results for "".
- FDA Limits Use of Nizoralhttps://practicaldermatology.com/news/20130730-fda_limits_use_of_nizoral/2459489/The FDA has limited the use of Nizoral (ketoconazole) oral tablets, warning that the oral tablets can cause severe liver injuries and adrenal gland problems and advising that it can lead to harmful drug interactions with other medications. FDA has approved label changes and added a new Medication Gu
- ASDS Reports High Patient Satisfaction with Soft Tissue Filler Procedureshttps://practicaldermatology.com/news/20130729-asds_reports_high_patient_satisfaction_with_soft_tissue_filler_procedures/2459490/Dermal filler treatments are among the highest rated in consumer satisfaction, according to survey data released by the American Society for Dermatologic Surgery. The ASDS Consumer Survey on Cosmetic Dermatologic Procedures asked more than 6,300 consumers for their opinions on cosmetic treatments in
- Positive Findings Published for Provectus Pharmaceuticals' PV-10https://practicaldermatology.com/news/20130726-positive_findings_published_for_provectus_pharmaceuticals_pv-10/2459491/Positive research conducted at the Moffitt Cancer Center with intralesional PV-10 has been published in PLOS ONE, an international, peer-reviewed, open-access, online publication,
- Mentor, Medicis Unveiling Joint New Physician Loyalty Programhttps://practicaldermatology.com/news/20130717-mentor_medicis_unveiling_joint_new_physician_loyalty_program/2459494/Mentor Worldwide, LLC and Valeant's Medicis division have entered into a Collaboration Agreement to form a joint physician loyalty program called the M2VP P
- Galen Acquires Local Dermal Analgesia Drug Synerahttps://practicaldermatology.com/news/20130716-galen_acquires_local_dermal_analgesia_drug_synera/2459495/Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, Inc., a wholly owned subsidiary of Nuvo Research Inc. Synera® is indicated for use on intact skin t
- ASDS Database Helps Residents Find Fellowships and Opportunitieshttps://practicaldermatology.com/news/20130716-asds_database_helps_residents_find_fellowships_and_opportunities/2459499/To help residents with the challenge of identifying suitable fellowship programs, the American Society for Dermatologic Surgery's (ASDS) new database, called the DermSurg Fellowship Finder, is a comprehensive source for all Mohs, procedural, cosmetic, and laser surgical fellowships in the US. The go
- Leading Scientist Behind SkinCeuticals Dies At 76https://practicaldermatology.com/news/20130712-dr_sheldon_pinnell_the_founding_father_of_topical_antioxidants_leading_scientist_behind_skinceuticals_and_chief_emeritus_of_the_division_of_dermatolog/2459500/Dr. Sheldon Pinnell, an internationally eminent scientist, dermatologist, leading scientist behind L'Oreal-owned SkinCeuticals, and J. Lamar Callaway Professor Emeritus of Dermatology and Chief Emeritus of the Division of Dermatology at Duke University, passed away peacefully in Durham, North Caroli
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,
- Allergan Appoints Douglas S. Ingram as Presidenthttps://practicaldermatology.com/news/20130702-allergan_appoints_douglas_s_ingram_as_president/2459504/Douglas S. Ingram was appointed as President of Allergan. In this role, Mr. Ingram will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer, and medical device product
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with